Cosmos Health Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and cash equivalents | $716K+127.1% | $315K-91.8% | $3.8M-81.5% | $20.7M |
| Restricted cash | $2.7M | $0 | — | — |
| Accounts receivable, net | $19.6M+45.6% | $13.5M-31.8% | $19.8M-16.6% | $23.7M |
| Accounts receivable - related party | $2.4M+98.6% | $1.2M+11.9% | $1.1M-59.4% | $2.7M |
| Marketable securities | $46K+118.3% | $21K+5.3% | $20K+34.9% | $15K |
| Inventory | $5.8M+32.7% | $4.4M-9.1% | $4.8M+38.7% | $3.5M |
| Loans receivable | $488K-20.6% | $614K+49.2% | $412K+9.2% | $377K |
| Loans receivable - related party | $0-100.0% | $557K+26.0% | $442K+3.4% | $428K |
| Prepaid expenses and other current assets | $2.0M+53.2% | $1.3M-27.7% | $1.8M+17.2% | $1.5M |
| Prepaid expenses and other current assets - related party | $4.5M+26.8% | $3.6M-19.4% | $4.4M+30.7% | $3.4M |
| TOTAL CURRENT ASSETS | $38.4M+50.8% | $25.5M-30.4% | $36.6M-35.1% | $56.4M |
| Property and equipment, net | $10.6M+9.2% | $9.7M-6.2% | $10.3M+468.6% | $1.8M |
| Goodwill and intangible assets, net | $7.6M-2.4% | $7.8M-0.7% | $7.8M+1004.5% | $707K |
| Digital assets | $1.4M | $0 | — | — |
| Loans receivable - long term portion | $3.1M+9.4% | $2.9M-18.0% | $3.5M-7.5% | $3.8M |
| Loans receivable - related party - long term | $0-100.0% | $2.9M-18.1% | $3.5M-8.1% | $3.9M |
| Operating lease right-of-use asset | $597K-14.3% | $696K-38.5% | $1.1M+5.8% | $1.1M |
| Financing lease right-of-use asset | $4K-71.8% | $14K-52.7% | $29K-33.2% | $43K |
| Advances for building's acquisition | $600K-70.0% | $2.0M+0.0% | $2.0M | $0 |
| Other assets | $1.5M+38.9% | $1.1M+4.8% | $1.1M+170.1% | $392K |
| Other assets - related party | $1.6M-9.3% | $1.8M | $0 | — |
| TOTAL ASSETS | $65.5M+20.6% | $54.3M-17.7% | $66.0M-3.0% | $68.0M |
| Accounts payable and accrued expenses | $14.6M+31.1% | $11.2M-6.3% | $11.9M+17.5% | $10.1M |
| Accounts payable and accrued expenses - related party | $2.0M+57.7% | $1.3M+448.2% | $232K+12.8% | $205K |
| Accrued interest | $786K+254.6% | $222K+33.3% | $166K-39.6% | $276K |
| Lines of credit | $9.2M+31.4% | $7.0M+5.4% | $6.6M+15.1% | $5.8M |
| Notes payable | $2.2M-14.0% | $2.5M+62.2% | $1.6M-27.2% | $2.2M |
| Notes payable - related party | $12K+13.4% | $11K-6.4% | $11K+3.4% | $11K |
| Loans payable - related party | $0-100.0% | $6K-53.3% | $13K+3.4% | $13K |
| Convertible notes payable | $2.1M | $0 | — | — |
| Derivative liability - convertible note | $1.3M | $0 | — | $54K |
| Operating lease liability, current portion | $222K+12.9% | $197K-31.1% | $286K+19.0% | $240K |
| Financing lease liability, current portion | $4K-66.4% | $11K-57.8% | $27K+10.8% | $25K |
| Other current liabilities | $5.8M+73.8% | $3.4M-3.6% | $3.5M+31.2% | $2.6M |
| TOTAL CURRENT LIABILITIES | $38.3M+48.6% | $25.8M+5.9% | $24.3M+11.8% | $21.7M |
| Notes payable - long term portion | $1.6M+1.5% | $1.6M-48.6% | $3.0M+6.1% | $2.9M |
| Convertible notes payable - long term portion | $4.3M | $0 | — | — |
| Operating lease liability, net of current portion | $373K-25.1% | $498K-41.0% | $845K+1.9% | $829K |
| Financing lease liability, net of current portion | $0-100.0% | $3K-35.4% | $5K-83.2% | $31K |
| Other liabilities | $2.6M+30.4% | $2.0M+11.1% | $1.8M+29.8% | $1.4M |
| TOTAL LIABILITIES | $47.1M+58.0% | $29.8M-0.6% | $30.0M+5.6% | $28.4M |
| Commitments and Contingencies (see Note 14) | $0 | $0 | $0 | $0 |
| Common stock, $0.001 par value;1,500,000,000 shares authorized; 41,153,809 and 23,689,135 shares issued and 41,067,312 and 23,602,638 outstanding as of December 31, 2025 and December 31, 2024, respectively | $41K+73.7% | $24K+48.2% | $16K+50.7% | $11K |
| Additional paid-in capital | $152.1M+7.5% | $141.6M+9.7% | $129.0M+15.0% | $112.2M |
| Subscription receivable | $0+100.0% | -$20+0.0% | -$20+100.0% | -$4.8M |
| Treasury stock, at cost, 86,497 shares as of December 31, 2025 and December 31, 2024 | -$917K+0.0% | -$917K | — | — |
| Accumulated deficit | -$133.2M-16.8% | -$114.0M-24.4% | -$91.6M-38.4% | -$66.2M |
| Accumulated other comprehensive income/(loss) | $332K+115.5% | -$2.1M-408.5% | -$420K+62.9% | -$1.1M |
| TOTAL STOCKHOLDERS' EQUITY | $18.4M-24.9% | $24.5M-31.9% | $36.0M-8.3% | $39.3M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $65.5M+20.6% | $54.3M-17.7% | $66.0M-3.0% | $68.0M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Cosmos Health reported record Q1 2026 revenue of $17.9M, up 31% year-over-year, with liabilities reduced by $4.5M and stockholders' equity up 7.6%
“Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-11-05:00 | 2026-06-12 | Siokas Grigorios | Director & Chief Executive Officer | Purchase | 218.4K | $0.21 | $45K | 13.48M | View | |
| 2026-06-10-05:00 | 2026-06-12 | Siokas Grigorios | Director & Chief Executive Officer | Purchase | 701.4K | $0.23 | $160K | 13.26M | View | |
| 2026-02-12-05:00 | 2026-02-13 | Siokas Grigorios | Director & Chief Executive Officer | Purchase | 388.5K | $0.37 | $145K | 8.86M | View | |
| 2026-02-11-05:00 | 2026-02-12 | Siokas Grigorios | Director & Chief Executive Officer | Purchase | 291.3K | $0.41 | $120K | 8.47M | View | |
| 2026-01-23-05:00 | 2026-01-26 | Siokas Grigorios | Director & Chief Executive Officer | Purchase | 90.3K | $0.50 | $45K | 8.18M | View |
Informational purposes only, not investment advice.